CLDN7 Antibody

What is CLDN7 and what are its key biological functions?

Claudin-7 (CLDN7) is a critical component of tight junctions in epithelial cells that plays a major role in tight junction-specific obliteration of the intercellular space . This structure regulates the movement of substances between epithelial cells, protecting tissues from pathogens and maintaining homeostasis. These tight junctions are integral in maintaining cell polarity and controlling the paracellular transport of ions and molecules .

CLDN7 demonstrates tissue-specific functions:

• In renal collecting duct cells: Regulates paracellular Cl- and Na+ permeability

• In intestinal epithelium: Essential for stem cell survival, self-renewal, and differentiation through modulation of Wnt/β-catenin signaling

• In multiple epithelia: Serves as a barrier maintenance protein with tissue-specific permeability properties

What applications are CLDN7 antibodies validated for in research?

CLDN7 antibodies are validated for multiple experimental applications as detailed below:

Most antibodies show membrane staining at cell-cell junctions, with specific enrichment at tight junction complexes .

How should researchers select the appropriate CLDN7 antibody for their experimental system?

Selection of the appropriate CLDN7 antibody requires careful consideration of multiple factors:

• Species reactivity: Verify antibody reactivity with your species of interest

  • Human-reactive: ab207300, ab265583, ab27487

  • Mouse-reactive: ab27487, 29795-1-AP

  • Rat-reactive: ab27487

• Antibody clonality:

  • Monoclonal antibodies (e.g., EPR18073 ab207300 ): Higher specificity, less batch variation

  • Polyclonal antibodies (e.g., ab27487 ): Recognize multiple epitopes, potentially higher sensitivity

• Validated applications: Confirm the antibody is validated for your specific application

  • For example, ab207300 is validated for ICC/IF, Flow Cyt, IHC-P

  • ab265583 is validated for IP and WB

• Epitope location: Consider whether the target epitope is relevant to your research question

  • C-terminal targeting: ab265583 targets amino acids 150 to C-terminus

  • This is particularly important for truncated protein studies or when using fusion tags

• Validation evidence: Review validation data including:

  • Western blot showing correct molecular weight (22-23 kDa)

  • Knockout/knockdown controls

  • Cross-reactivity testing

What controls are essential when working with CLDN7 antibodies?

Proper experimental controls are critical for interpreting CLDN7 antibody data:

Positive Controls:

• Tissue sections: Human/mouse colon , kidney , breast, fallopian tube, pancreas

• Cell lines: MCF7 (human breast adenocarcinoma), LNCap, HepG2 (liver hepatocellular carcinoma)

Negative Controls:

• Procedural: Omit primary antibody while maintaining secondary antibody

• Biological: CLDN7 knockout or knockdown samples when available

• Technical: Isotype-matched irrelevant antibodies

Validation Controls:

• Peptide competition: Pre-incubation with immunizing peptide should abolish specific signal

• Multiple detection methods: Confirm findings using different techniques (e.g., IF and WB)

• Knockout validation: Test antibody on CLDN7-/- cells or tissues if available

Example validation protocol from literature:
Immortalized CLDN7+/+ CD cells show strong CLDN7 immunostaining at cell-cell contact areas, while CLDN7-/- CD cells show absence of signal, confirming antibody specificity .

Advanced Research Methodologies and Techniques

The experimental design for CLDN7 knockout/knockdown studies requires careful controls and validation:

Experimental Models Available:

• Conditional knockout mouse models:

  • IEC-specific: Cldn7fl/fl;Villin-CreERT2

  • ISC-specific: Cldn7fl/fl;Lgr5-CreERT2

• Cell-based models:

  • Immortalized CLDN7+/+ and CLDN7-/- CD cells

  • CLDN7 shRNA knockdown models

Validation Methodology Pipeline:

• Expression verification: Confirm CLDN7 knockout/knockdown at both mRNA (qRT-PCR) and protein levels (Western blot, immunofluorescence)

• Functional assessment: Measure consequences of CLDN7 deletion

  • Paracellular permeability: TER and dilution potential measurements

  • Molecular changes: WNK4, SGK-1, ENaC expression levels

  • Cellular behavior: Migration, invasion assays

  • Stem cell markers: Lgr5, Olfm4, Sox9, Prom1, Hopx expression

• Rescue experiments: Re-express CLDN7 in knockout/knockdown cells to confirm phenotype specificity

  • Example from literature: Transfection of CLDN7 into knockdown cells restored Cl- and Na+ permeability to 91.1% and 90.4% of control values, respectively

• Off-target effect monitoring: Assess expression of related claudins (CLDN3, CLDN4) and other tight junction components to detect compensatory mechanisms

What methodological approaches verify CLDN7 antibody specificity?

Establishing CLDN7 antibody specificity requires a multi-faceted validation approach:

Genetic Validation Methods:

• Use of CLDN7 knockout tissues or cells (gold standard)

• CLDN7 knockdown via siRNA or shRNA with quantitative assessment of signal reduction

Biochemical Validation Methods:

• Western blot: Verification of single band at expected molecular weight (22-23 kDa)

• Peptide competition: Pre-incubation with immunizing peptide should abolish signal

• Immunoprecipitation followed by mass spectrometry to confirm target identity

Multi-antibody Validation:

• Comparison of staining patterns with multiple antibodies targeting different CLDN7 epitopes

• Example: Compare results between monoclonal (ab207300) and polyclonal (ab27487) antibodies

Cross-reactivity Testing:

• Test against related claudin family members (especially CLDN3, CLDN4)

• Evaluate signal in tissues known to lack CLDN7 expression

Example Validation Data from Literature:
CLDN7+/+ CD cells show strong CLDN7 immunostaining at cell-cell contacts, while CLDN7-/- CD cells show no signal. CLDN3, CLDN4, and AQP2 expression patterns remained unchanged, confirming antibody specificity .

What analytical methods are recommended for quantifying CLDN7 expression in complex tissues?

Quantification of CLDN7 expression in heterogeneous tissues requires appropriate analytical methodologies:

Immunohistochemistry/Immunofluorescence Quantification:

• Digital image analysis with membrane-specific algorithms (CLDN7 is primarily membrane-localized)

• Cell-type specific quantification using co-staining with lineage markers

• H-score method: Intensity (0-3) × percentage of positive cells (0-100%)

Biochemical Quantification:

• Western blot with densitometry analysis normalized to loading controls (GAPDH)

• ELISA-based quantification:

  • Serum CLDN7 levels in CRC patients were significantly lower than in healthy controls (8.92 vs. 72.1 pg/mL)

  • Important finding: Some patients had CLDN7 levels below detection limit

mRNA Expression Analysis:

• qRT-PCR with 2-ΔΔCt normalization method

• Cell-type specific analysis using laser-capture microdissection

• Single-cell RNA-seq for heterogeneous tissues

Flow Cytometry Analysis:

• Intracellular staining protocol with appropriate permeabilization

• Median fluorescence intensity (MFI) for quantitative comparison

• Example antibody validated for flow cytometry: ab207300

Standardization Recommendations:

• Include calibration standards when possible

• Process all experimental groups simultaneously

• Use automated imaging and analysis platforms for consistency

• Document all acquisition parameters for reproducibility

How is CLDN7 transcriptionally regulated and what implications does this have for antibody detection studies?

Understanding CLDN7 transcriptional regulation provides important context for antibody-based studies:

Key Transcriptional Regulators:

• Hepatocyte nuclear factor 4α (HNF4α) directly regulates CLDN7 during intestinal epithelial cell differentiation

• Additional transcription factors identified in screening:

  • PU.1 and Oct 2.1 also bind the CLDN7 promoter

Promoter Characteristics:

• CLDN7 promoter region spans -3072 to -1 bp, with transcription start site at -1150 bp

• Has been cloned into luciferase reporter vectors for functional analysis

Expression Dynamics:

• CLDN7 expression increases during epithelial cell differentiation

• Dysregulation in disease states alters expression patterns

Implications for Antibody Studies:

• Consider differentiation state when interpreting expression data

• Use appropriate developmental stage-matched controls

• Account for tissue-specific regulation (HNF4α in intestine vs. other tissues)

• Combine transcriptional analysis with protein detection for comprehensive studies

What functional assays can be paired with CLDN7 antibody studies to assess tight junction integrity?

Combining CLDN7 antibody detection with functional assays provides deeper insight into tight junction biology:

Electrical Impedance Measurements:

• Transepithelial electrical resistance (TER):

  • Measures ionic permeability across epithelial monolayers

  • CLDN7-/- CD cells showed significantly increased TER compared to CLDN7+/+ cells

Paracellular Permeability Assays:

• Dilution potential measurements:

  • Calculated using the Goldman–Hodgkin–Katz equation

  • CLDN7 deletion decreased dilution potential in CD cells

• Ion permeability determination:

  • CLDN7-/- cells showed decreased Cl- and Na+ permeability

  • Rescue with CLDN7 restored permeability to ~90% of control values

Molecular Function Tests:

• Protein-protein interaction analysis:

  • CLDN7 forms a complex with WNK4 in kidney cells

  • Deletion of CLDN7 significantly increased WNK4, SGK-1, and ENaC-α mRNA and protein levels

Cellular Behavior Assays:

• Migration assays:

  • CLDN7 knockdown increased cell migration in ovarian cancer cells

• Invasion assays:

  • CLDN7 knockdown reduced invasive potential of ovarian cancer cells

  • CLDN7 overexpression increased invasion in OV-90 cells

Barrier Recovery Assessments:

• Calcium switch assay: Measures tight junction reassembly dynamics

• Wound healing with CLDN7 antibody staining: Visualizes recruitment during barrier formation

What methodologies can identify CLDN7 protein-protein interactions in tight junctions?

Several advanced techniques can reveal CLDN7's protein interaction network:

Immunoprecipitation-Based Methods:

• Standard co-IP:

  • CLDN7 immunoprecipitation from cell lysates has been demonstrated

  • Can identify stable interactions but may miss transient or weak interactions

Proximity-Based Detection:

• BioID/TurboID:

  • Fusion of biotin ligase to CLDN7 labels proximal proteins

  • Particularly valuable for membrane protein interactions

• APEX2 proximity labeling:

  • Rapid biotin labeling for capturing dynamic interactions

Advanced Imaging Approaches:

• Förster resonance energy transfer (FRET):

  • Detects direct protein-protein interactions (<10 nm)

  • Requires fluorophore-tagged proteins

• Proximity ligation assay (PLA):

  • Visualizes protein interactions in situ with high sensitivity

  • Useful for detecting endogenous protein complexes

Biophysical Methods:

• Surface plasmon resonance (SPR):

  • Measures binding kinetics between CLDN7 and potential partners

  • Requires purified proteins

Functional Validation:

• Correlation with paracellular permeability measurements:

  • CLDN7-WNK4 interaction affects ion permeability in renal CD cells

• Mutagenesis of interaction domains:

  • Can map specific interaction sites

Proteomics Approaches:

• Mass spectrometry following CLDN7 pulldown:

  • Identifies interaction partners with high sensitivity

• Cross-linking mass spectrometry:

  • Captures transient interactions through chemical cross-linking

How do post-translational modifications of CLDN7 affect antibody detection and function?

Post-translational modifications (PTMs) of CLDN7 can significantly impact both antibody detection and protein function:

Phosphorylation:

• WNK4 kinase interacts with CLDN7, suggesting potential phosphorylation

• Phosphorylation status may affect:

  • Antibody epitope accessibility

  • Tight junction assembly and stability

  • Paracellular permeability properties

Palmitoylation:

• Claudins undergo palmitoylation which affects their localization

• May influence extraction efficiency in biochemical assays

• Could impact membrane microdomain distribution and protein interactions

Ubiquitination:

• Regulates claudin protein turnover and degradation

• May create differential detection patterns depending on antibody epitope

Glycosylation:

• Potential N-glycosylation can affect antibody binding

• May influence protein stability and trafficking

Methodological Considerations:

• Epitope-specific antibodies may be differently affected by PTMs

• Sample preparation (particularly lysis conditions) should preserve PTMs of interest

• Phosphatase/deubiquitinase inhibitors should be included during cell/tissue lysis

• Phospho-specific antibodies may be valuable for functional studies

Experimental Troubleshooting and Advanced Applications

Flow cytometric analysis of CLDN7 requires specific protocol adaptations:

Cell Preparation Considerations:

• Gentle dissociation methods to preserve membrane integrity

• Fixation optimization:

  • 2-4% paraformaldehyde (10-15 minutes)

  • Avoid methanol fixation which can extract membrane lipids

• Permeabilization protocol:

  • 0.1-0.5% saponin or 0.1% Triton X-100

  • Critical for accessing junction-associated CLDN7

Antibody Selection:

• Use antibodies validated for flow cytometry

  • ab207300 is specifically validated for intracellular flow cytometry

• Titrate antibody concentration to optimize signal-to-noise ratio

Staining Protocol:

• Fix single-cell suspension (2-4% PFA, 10-15 min)

• Permeabilize with 0.1% saponin in PBS + 2% BSA

• Block with 5-10% normal serum (match secondary antibody species)

• Incubate with primary anti-CLDN7 antibody (optimized concentration)

• Wash thoroughly (3X)

• Incubate with fluorophore-conjugated secondary antibody

• Wash thoroughly (3X)

• Analyze with appropriate controls

Essential Controls:

• Unstained cells (autofluorescence control)

• Isotype control (non-specific binding)

• Secondary-only control (background)

• Positive control (CLDN7-expressing cell line)

• Negative control (CLDN7-negative cell line or knockdown)

Data Analysis Approach:

• Gating strategy should account for intact cells (FSC/SSC)

• Measure median fluorescence intensity rather than just percent positive

• Consider bimodal distribution in heterogeneous populations

How can CLDN7 antibodies be effectively used in multiplexed imaging?

Multiplexed detection of CLDN7 with other markers requires careful protocol development:

Antibody Panel Design:

• Select antibodies from different host species when possible

• For same-species antibodies, consider:

  • Sequential staining with intermediate blocking

  • Directly conjugated primary antibodies

  • Zenon labeling technology for same-species antibodies

Recommended Marker Combinations:

• Tight junction complex: CLDN7 + CLDN3/4 + ZO-1

• Epithelial differentiation: CLDN7 + HNF4α + differentiation markers

• Cancer analysis: CLDN7 + proliferation markers + EMT markers

Multiplexing Methods:

• Fluorescence-based:

  • Standard multicolor immunofluorescence (3-4 colors)

  • Spectral imaging for increased marker density

  • Cyclic immunofluorescence for >10 markers

• Chromogenic:

  • Sequential chromogenic IHC with stripping/blocking

  • Multispectral imaging to separate overlapping chromogens

Validation for Multiplexed Staining:

• Single staining controls to verify antibody performance

• Absorption controls to confirm specificity

• Comparison with single-plex staining patterns

Image Acquisition and Analysis:

• Confocal microscopy for colocalization analysis

• Super-resolution techniques for detailed junction analysis

• Automated image analysis with membrane-specific algorithms

Example Multiplexing Application:
Study examining CLDN7 and WNK4 colocalization would combine CLDN7 antibody with WNK4 antibody, illustrating their association in renal collecting duct cells as described in the literature .

What considerations apply when using CLDN7 antibodies in clinical biomarker research?

CLDN7 has potential as a clinical biomarker, requiring specific methodological considerations:

Biomarker Development Pipeline:

• Discovery phase: Identify differential expression in disease states

  • CLDN7 downregulation in colorectal, lung, esophageal, head/neck, prostate cancers

  • CLDN7 overexpression in ovarian cancers

• Analytical validation:

  • Antibody specificity and sensitivity testing

  • Reproducibility across laboratories

  • Assay standardization (IHC protocols, scoring systems)

• Clinical validation:

  • Correlation with clinical outcomes

  • Comparison with standard markers

  • Validation in independent cohorts

CLDN7 as Tissue Biomarker:

• Immunohistochemical scoring:

  • Standardized scoring system (H-score, Allred, etc.)

  • Membrane vs. cytoplasmic localization assessment

  • Digital pathology quantification for reproducibility

CLDN7 as Liquid Biopsy Biomarker:

• Serum CLDN7 levels detected by ELISA:

  • Significantly lower in CRC patients (8.92 pg/mL) vs. healthy controls (72.1 pg/mL)

  • ROC curve analysis showed good diagnostic accuracy (AUC = 0.763)

  • Some patients had levels below detection limit

Pre-analytical Variables:

• Tissue processing standardization

• Fixation time and conditions

• Sample storage considerations

• Batch effects monitoring

Analytical Variables:

• Antibody clone selection and validation

• Detection system optimization

• Automated vs. manual staining platforms

• Computer-assisted scoring

Example Research Application:
Double-antibody sandwich ELISA method for serum CLDN7 detection showed potential diagnostic value for colorectal cancer with good accuracy (AUC = 0.763), suggesting clinical utility as a minimally invasive biomarker .

What emerging technologies are advancing CLDN7 research beyond traditional antibody methods?

Recent technological developments are expanding CLDN7 research capabilities:

CRISPR-Based Technologies:

• CRISPR knockout models provide superior specificity compared to siRNA approaches

• CRISPR activation/inhibition for modulating CLDN7 expression without genetic deletion

• CRISPR screening to identify CLDN7 regulatory factors

Advanced Imaging Techniques:

• Super-resolution microscopy (STORM, PALM) for nanoscale junction visualization

• Lattice light-sheet microscopy for dynamic 3D imaging of junction assembly

• Correlative light-electron microscopy for ultrastructural analysis

Single-Cell Analysis:

• Single-cell RNA-seq for expression heterogeneity analysis

• Single-cell proteomics for protein-level heterogeneity assessment

• Spatial transcriptomics to maintain tissue context

Organoid Technologies:

• Patient-derived organoids for personalized CLDN7 studies

• Intestinal organoids from CLDN7 conditional knockout mice show stem cell defects

• Co-culture systems to study epithelial-stromal interactions

Emerging Therapeutic Approaches:

• Targeted antibody therapeutics based on accessible extracellular loops

• Claudin-targeted peptide mimetics for junction modulation

• Gene therapy approaches to restore CLDN7 in deficient tissues

These emerging technologies complement traditional antibody-based methods and provide opportunities for more comprehensive understanding of CLDN7 biology.

What are the most critical methodological gaps in current CLDN7 research?

Despite significant advances, several methodological challenges remain in CLDN7 research:

Technical Limitations:

• Lack of standardized quantification methods for junction proteins

• Limited availability of phospho-specific antibodies for CLDN7

• Challenges in membrane protein extraction while preserving native conformation

Biological Complexity Challenges:

• Difficulty distinguishing junctional vs. non-junctional CLDN7 pools

• Limited understanding of CLDN7 dynamics during junction assembly/disassembly

• Incomplete characterization of tissue-specific CLDN7 binding partners

Translational Research Gaps:

• Need for improved CLDN7 biomarker standardization across laboratories

• Limited prospective studies validating CLDN7 as diagnostic/prognostic marker

• Lack of standardized protocols for CLDN7 assessment in clinical samples

Future Methodological Priorities:

• Development of live-cell imaging tools for CLDN7 dynamics

• Improved methods for studying CLDN7 in heterogeneous tissues

• Standardized protocols for clinical biomarker applications

• Advanced multiplexing approaches for comprehensive junction analysis

• Development of CLDN7-targeted therapeutic delivery systems

Addressing these methodological gaps will accelerate both basic understanding of CLDN7 biology and its translational applications.